Holen Sie sich die Stockscreener-App
208.46
0.27%
1.11
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Quest Diagnostics Inc Aktie (DGX) Neueste Nachrichten
Quest Diagnostics stock holds steady as diagnostics demand supports long-term growth - Ad Hoc News
Quest Diagnostics (NYSE:DGX) Offers a Secure and Sustainable Dividend with Strong Profitability - ChartMill
Quest Diagnostics (DGX) Proxy filing Summary - Quartr
Quest Diagnostics (DGX) Q4 2025 earnings summary - Quartr
Marijuana drives half of 2025 worker hair drug positives as fentanyl rates fall - Stock Titan
Quest Diagnostics stock stays supported by steady diagnostics demand - Ad Hoc News
Quest Diagnostics steadies its business model as demand for testing evolves - Ad Hoc News
Quest Diagnostics Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Quest Diagnostics updates digital tools as testing demand evolves - Ad Hoc News
Quest Diagnostics Incorporated Integrates Oncology Test Access with Flatiron Health Oncoemr for American Oncology Network - marketscreener.com
Quest Diagnostics Now the Largest Clinical Reference Lab to Extend Oncology Test Access Through OncoEMR MPI - marketscreener.com
Quest Diagnostics (DGX) Q4 2024 earnings summary - Quartr
Quest Diagnostics Inc. stock outperforms competitors despite losses on the day - MarketWatch
Quest Diagnostics highlights its diagnostics role as investors assess the health services sector - ad-hoc-news.de
Quest Diagnostics stock steady as investors await the next catalyst - Ad Hoc News
Quest Diagnostics Quantiferon-TB Gold Pluslab test quietly underpins US tuberculosis screening - ad-hoc-news.de
Quest Diagnostics highlights long-term testing role in U.S. healthcare - ad-hoc-news.de
DGXQuest Diagnostics Inc Volatility & Greeks - Finviz
Quest Diagnostics Incorporated (DGX) hits fresh high: Is there still room to run? - MSN
If You Invested $1,000 in Quest Diagnostics Inc (DGX) - Stock Titan
Quest Diagnostics outlines its role in medical testing as investors weigh long-term demand - ad-hoc-news.de
Quest Diagnostics highlights its role in US healthcare. The stock reflects a stable diagnostics busi - Ad Hoc News
Director Timothy Wentworth receives 144 DGX phantom units as deferred pay - Stock Titan
Quest Diagnostics steadies after recent volatility as investors focus on core testing business - ad-hoc-news.de
Quest Diagnostics Incorporated (DGX) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
Quest Diagnostics Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Fund Update: 111,974 QUEST DIAGNOSTICS (DGX) shares added to EASTERN BANK portfolio - Quiver Quantitative
Quest Diagnostics's Q2 2026 Earnings: What to Expect - inkl
Quest Diagnostics (DGX) Q1 2025 earnings summary - Quartr
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch
Quest Diagnostics earnings calendar in focus, shares trade steadily on the NYSE - Ad Hoc News
Price to earnings forward of Quest Diagnostics Incorporated – NYSE:DGX - TradingView
Quest Diagnostics highlights long-term strategy, shares hold near recent highs - ad-hoc-news.de
ETFs Investing in Quest Diagnostics Incorporated Stocks - TradingView
Quest Diagnostics Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Quest Diagnostics (DGX) Wins Nationwide Haystack MRD Access And Expands Into Psychiatry - Yahoo Finance
Quest Diagnostics Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Quest Diagnostics Incorporated Actuals & Estimates (NYSE:DGX) - TradingView
Days After Launch, Attunio Health Expands Precision Psychiatry Infrastructure with Quest Diagnostics and Getlabs - Morningstar
DGX Forecast — Price Target — Prediction for 2027 - TradingView
Quest Diagnostics Inc (DGX) Stock Up 3.0% but GF Value Says Over - GuruFocus
Quest Diagnostics Receives New York Clearance for Haystack MRD Test - marketscreener.com
Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing - PR Newswire
Quest Diagnostics updates 2025 guidance, shares trade near record valuation levels - Ad-hoc-news.de
New York clears Quest Diagnostics' cancer recurrence test statewide - Stock Titan
Is it Apt to Hold Quest Diagnostics Stock in Your Portfolio Now? - TradingView
Quest Diagnostics Prevails in Appeal Over 401(k) Fund Options - Bloomberg Law News
Quest Diagnostics StockWeekly outlook with earnings ahead - AD HOC NEWS
Is Quest Diagnostics Stock Underperforming the S&P 500? - inkl
Quest Diagnostics Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Study: UTI bacteria resist three common oral antibiotics - Stock Titan
UTI-causing Bacteria Resistant to Current Drugs, Finds National Study by Hackensack Meridian CDI and Quest Diagnostics - PR Newswire
Quest Diagnostics to Release Second Quarter Financial Results on July 23, 2026 - GuruFocus
Quietly smarter diagnostics, Quest Diagnostics Quanum Enterprise Content Manager streamlines lab wor - AD HOC NEWS
Quest Diagnostics Inc (DGX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Quest Diagnostics Inc (DGX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Quest Diagnostics Inc (DGX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Quest Diagnostics Inc (DGX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Quest Diagnostics Inc (DGX) Institutional Confidence - TradingKey
Quest Diagnostics Inc (DGX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Quest Diagnostics Inc (DGX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Quest Diagnostics Inc (DGX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Quest Diagnostics Inc (DGX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
0.42%
0.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):